Media Room

We are committed to providing reliable, accurate, and interesting news and information. If you don’t find what you need, contact us for information, ideas, resources, artwork, interviews, or just answers to questions about Regenexx.

For press inquiries, please contact:
Kerry Flagg
[email protected]

Note to Reporters: The procedures using Regenexx injectates currently being offered in the US are 1271.15(b) compliant (same surgical procedure) and not considered a 351 drug by FDA. The only procedure using a Regenexx injectate considered a drug by FDA was the procedure using culture expanded stem cells, which has not been performed in the U.S. since 2010. For more information on Regenexx, please visit Our Approach.

Results And Research

We are leaders in interventional orthopedic research for orthopedics and we track patients (who have opted in) with Regenexx protocol in a outcomes registry and publishing the results: the good results as well as the treatment failures. Here are some examples of easy to read patient infographics that provide these outcome details on many treated patients:

Patient Treatment Registry Outcome Data

For our research articles published in medical research journals – Click Here